Monday , June 27 2022

EndoPredict ® predicts the chemotherapy benefit in women with early negative-positive cancer, HER2-negative breast cancer



[ad_1]

A new study has found many women may get unnecessary chemotherapy treatment

(MyGad: MYGN), a global leader in personalized medicine, today announced an international team of cancer researchers that found EndoPredict® Accurate testing predicts that women with ER-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy. The findings were published today in the journal Breast Cancer Research And Treatment.

"We are happy to publish our findings because ER-positive breast cancer, positive for HER2, is the most common type of breast cancer, and a key goal is to identify which women need endocrine therapy alone, who need endocrine therapy plus chemotherapy to get the best results. "Said Dr. William G. Gradisher, co-author of the study and director of the Department of Hematology and Oncology, the Department of Medicine, Professor Betsy Barmsen of Breast Oncology and Professor of Medicine at Feinberg School of Medicine." Our study showed that the EndoPredit test could accurately identify patients who may To benefit from the edge chemotherapy Test EndoPredict can use to customize their care by directing chemotherapy for women with a high likelihood of benefit, while avoiding overtreatment of women who are likely to benefit. "

This study evaluated the ability of the EndoPredict (EPclin) test to predict a chemotherapeutic benefit based on the 10-year relapse rate (metastasis) in women with HER2 negative breast cancer who received 5 years of endocrine therapy alone or in combination with chemotherapy (ET + C). Data from 3,746 women (2,630 in ET alone and 1,116 in ET + C) were included in the analysis. The study found that women with a high endoPredict score (ie, 3.3) receiving ET + C had a significantly lower risk for 10 years than those in ET alone (Figure 1). However, no significant differences were found between ET + C and ET for patients with low EndoPredict scores, indicating that these women would not benefit from chemotherapy therapy.

In this analysis with modern chemotherapy regimens, patients with high EndoPredict scores who received endocrine therapy and chemotherapy had significantly better outcomes than those who received endocrine therapy alone, "says Ivana Sestak, lead investigator at the Cancer Prevention Center, Wolfson Institute of Preventive Medicine, Queen Mary University of London. Based on these findings, oncologists should use the EndoPredit test to make decisions about the best treatment for their patients.

Figure 1: EndoPredict® Viewing chemotherapy in women with ER +, breast cancer is available at the following address:

http://www.globenewswire.com/NewsRoom/AttachmentNg/92035128-381e-4220-91c9-1e015196dfb4

"EndoPredict is an advanced test for exact medicine, and is the only test with the scientific criterion to provide superior risk stratification to patients with node +/- breast cancer to identify patients who can safely give up prolonged endocrine therapy after five years and importantly, "Said Jonathan Lancaster, MD, Ph.D., Chief Medical Officer, Myriad Genetics. "EndoPredict is covered by almost all health insurers in the United States because they identified EndoPredit's ability to meet unmet medical needs, improving the health outcomes of women and potentially saving health systems tens of millions of dollars."

The EndoPredit test has recently been included in the guidelines of the National Cancer Network (NCCN) for breast cancer. Follow Myriad on Twitter with @MyriadGenetics to keep up with news and updates from the company.

About breast cancer
One in eight American women will have breast cancer during her lifetime. Breast cancer is the second leading cause of cancer death among American women. The American Cancer Society estimates its cancer facts and 2019 reports that more than 268,000 women will be told they have breast cancer in 2019.

About EndoPredict®
EndoPredict is a second-generation, prognostic test that helps in designing customized therapy for patients with early stage breast cancer. EndoPredict has verified over 3500 patients with negative negative junction disease and positive node is the leading breast prognosis in Europe. Unlike first-generation prognostic tests, EndogPredict tests incorporate a 12-gene molecular score with known prognostic factors and tumor size. In clinical studies, EndoPredict has demonstrated its robust ability to predict the risk of recurrence over several time periods: 0-5, 5-10, 5-15 years. EndoPredict provides clinical information for clinicians and patients when they see use of adjuvant chemotherapy and endotracheal endotracheal therapy.

About Genetics
Myriad Genetics Inc., is a leading personal medicine company dedicated to becoming a trusted consultant and transforming the lives of the patient worldwide with pioneering molecular diagnostics.Myriad discovers and commercializes molecular diagnostic assays that determine the risk of developing disease, accurately diagnose the disease, assess the risk of progression And focuses treatment decisions on six major clinical specialties, where molecular diagnosis can significantly improve patient care and lower health costs.Myriad focuses on five critical success factors: building a solid hereditary solid base, increasing new product volume, extending product reimbursement coverage New, increasing income The world of RNA and improve profitability through Elevate 2020.

A huge number, the Marian logo, Bart, LightningSurgeryMyCisk, myCoice, myPlan, BACAnalysis, CDM, BACAnalysis, MyChoice, HRD, EndoPredict, Vectra, GeneSight, RiskScore, ProLaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. Wholly owned subsidiaries in the United States and in foreign countries. MYGN-F, MYGN-G.

Oncotype Dx is a registered trademark of Genomic Health, Inc.

Safe Harbor Statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements concerning physicians who can use EndoPredit to customize their treatment by referring chemotherapy to women who are highly likely to benefit, Women who are unlikely to benefit; Oncologists who use the EndoPredit test to make decisions about the best treatment for their patients; EndoPredit provides an excellent risk stratification for patients with cancer of the node +/- breast cancer, which identifies them can safely abandon extended endocrine therapy after five years and predict chemotherapeutic benefit; The ability of EndoPredict to meet unmet medical needs, improve the health outcomes of women and potentially save health systems tens of millions of dollars; And its strategic guidelines under the heading "About Genetics". These forward-looking statements are based on management's current expectations regarding future events and are exposed to a number of risks and uncertainties that could cause the actual results to be materially different from those specified or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and of pharmaceutical and clinical services may decrease; Risks associated with our ability to migrate from our existing portfolio to our new tests, including unexpected costs and delays; Risks associated with decisions or changes in the reimbursement levels of government or private insurers for our tests or our ability to recover our new tests at equivalent levels for our existing tests; Risks related to increased competition and the development of testing and new competing services; The risk that we may be able to develop or achieve commercial success for further molecular diagnostic tests and clinical pharmaceutical services at the time, or at all; The risk that we will not be able to successfully develop new markets for our molecular diagnostic tests and medical and clinical services, including our ability to generate revenue outside the United States; The risk that the technology licenses that meet our molecular diagnostic tests and clinical pharmaceutical services and any future tests and services are either terminated or can not be maintained in satisfactory conditions; Risks associated with delays or other problems in the operation of our laboratory testing facilities and our health clinic; Risks associated with public concern about genetic testing in general or for our particular tests; Risks related to regulatory or enforcement requirements in the United States and foreign countries and changes in the structure of the health system or health payment systems; Risks associated with our ability to obtain new partnerships or licenses of the Company and to acquire new technologies or businesses under satisfactory conditions, if any; Risks associated with our ability to successfully integrate and benefit from all the technologies or businesses that we acquire or acquire; Risks associated with our projections of our business, operating results and financial position; Risks associated with potential market opportunities for our products and services; The risk that we or our licensors will not be able to protect or that third parties will harm the proprietary technologies underlying our testing; The risk of patent infringement claims or challenges to the validity of our patents or other intellectual property; Risks associated with changes in intellectual property laws to our molecular diagnostic tests and to pharmaceutical and clinical services and to patents or enforcement in the United States and other countries, such as the Supreme Court's decision in a lawsuit filed against us by the Society for Molecular Pathology et al. ; Risks of new, changing and competitive technologies in the US and the US, the risk that we will not be able to meet the financial covenants under our credit or loan agreements, the risk that we will not be able to pay, on maturity, amounts due under our credit or loan agreements; The heading "Risk Factors" included in Section 1A of our last annual report on Form 10-K for the fiscal year ended June 30, 2018, which was submitted to the Israel Securities Authority, as well as any update to these risk factors submitted from time to time in our quarterly reports on Form 10-Q or the current report On Form 8-K. All the information in this notice is correct as of the date they became black , And Myriad does not undertake to update this information unless required by this law.

Media Contact: Ron Rogers Investors Contact: Scott Gleason
(801) 584-3065 (801) 584-1143
[email protected] [email protected]


Source: Myriad Genetics, Inc.

[ad_2]
Source link